Both CD47 and CD24 are antiphagocytic factors overexpressed in several cancers such as non-small-cell lung cancer, and breast and ovarian cancer.

In a recent publication in Scientific Reports, researchers at City of Hope and collaborators presented a novel CS1 bsAb, called CS1-dbBiTE, conjugating an intact anti-CS1 antibody (elotuzumab) and an anti-human OKT3 antibody at their respective hinge regions using Click chemistry.

High expression of CD123, the IL-3 receptor α chain (IL-3α), is observed on both leukemic blasts and leukemic stem cells, thus suggesting it can be considered an attractive therapeutic target in AML.

Researchers from Seoul National University presented results of preclinical evaluation of a new TNF-α/OX40L bispecific antibody, IMB-101, being developed for the treatment of rheumatoid arthritis (RA).

Ibio Inc. has expanded its artificial intelligence (AI)-powered technology offering with the launch of Shieldtx, an antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue.

Researchers from Biontech SE and Genmab BV presented the discovery and preclinical evaluation of a novel Duobody-EpCAMx4-1BB (BNT314/GEN1059), a novel Fc-inert immunomodulatory bispecific antibody (bsAb) designed to boost antitumor immune responses through EpCAM-dependent 4-1BB agonistic activity.

Data regarding an innovative bispecific antibody – CPL-976 (CPBT-0976) – were recently reported by Celon Pharma SA. Bispecific antibodies targeting more than one antigen on cancer cells improve the specificity and effectiveness of the therapy, and could be utilized for targeting the defense mechanisms of cancer cells, such PD-L1 or EGFR, VEGFR and AXL.

Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Adimab LLC to discover and develop innovative antibody drugs in the oncology field.

Novarock Biotherapeutics Ltd., a subsidiary of CSPC Pharmaceutical Group Ltd., has received FDA approval of its IND application for NBL-028, a CLDN6-CD137 bispecific antibody.